Genmab Announces Net Sales of DARZALEX® (daratumumab) for the Third Quarter of 2022
yahoo.com
news
2022-10-18 10:35:00

Genmab A/S

Company Announcement

Net sales of DARZALEX ® in the third quarter of 2022 totaled USD 2,052 million

Genmab receives royalties on worldwide net sales from Janssen Biotech, Inc. (Janssen)

COPENHAGEN, Denmark; October 18, 2022 – Genmab A/S (Nasdaq: GMAB) announced today that worldwide net trade sales of DARZALEX® (daratumumab), including sales of the subcutaneous (SC) product (daratumumab and hyaluronidase-fihj, sold under the tradename DARZALEX FASPRO® in the U.S.), as reported by Johnson & Johnson were USD 2,052 million in the third quarter of 2022.
